NASDAQ: DWTXDogwood Therapeutics Inc Stock
$1.57+0.03 (+1.95%)
Updated Jun 15, 2026
DWTX Price
$1.57
Fair Value Price
$0.77
Market Cap
$52.80M
52 Week Low
$1.28
52 Week High
$9.50
P/E
2.85x
P/B
0.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$28.32M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$16M
Beta
0.85
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DWTX Overview
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DWTX's potential to beat the market
- DWTX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DWTX
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important DWTX news, forecast changes, insider trades & much more!
DWTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DWTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DWTX ($1.57) is overvalued by 102.85% relative to our estimate of its Fair Value price of $0.77 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DWTX ($1.57) is not significantly undervalued (102.85%) relative to our estimate of its Fair Value price of $0.77 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DWTX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more DWTX due diligence checks available for Premium users.
Valuation
DWTX fair value
Fair Value of DWTX stock based on Discounted Cash Flow (DCF)
Price
$1.57
Fair Value
$0.77
Overvalued by
102.85%
DWTX ($1.57) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DWTX ($1.57) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DWTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
2.85x
Industry
16.41x
Market
14.3x
DWTX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DWTX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
DWTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.65x
Industry
4.89x
DWTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DWTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.0M
Profit Margin
0%
DWTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$95.2M
Liabilities
$14.6M
Debt to equity
0.18
DWTX's short-term assets ($15.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DWTX's short-term assets ($15.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DWTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DWTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.6M
Investing
$0.0
Financing
$11.3M
DWTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DWTX vs Biotech Stocks
Dogwood Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.